公开(公告)号：US12091437B2

公开(公告)日：2024-09-17

申请号：US18390884

申请日：2023-12-20

申请人： Larimar Therapeutics, Inc.

发明人： Joan David Bettoun ,  Rebecca Wissner

IPC分类号： C07K14/47 ,  A61K38/00 ,  A61K47/64 ,  C07K14/005 ,  C12N9/10

CPC分类号： C07K14/47 ,  A61K47/64 ,  C07K14/005 ,  C12N9/104 ,  C12Y203/02 ,  A61K38/00 ,  C07K2319/02 ,  C07K2319/07 ,  C07K2319/50 ,  C12N2740/16322

摘要： The present disclosure provides a fusion protein useful for treating a non-nuclear organelle associated disorder, such as a genetic disorder, e.g., Friedrich's Ataxia. The fusion protein may comprise a protein of interest to be delivered to a non-nuclear organelle; an organelle targeting sequence (OTS); a cell penetrating peptide (CPP); and a target enhancing sequence (TES); wherein the CPP is capable of interference with delivery of the protein of interest to the non-nuclear organelle; and wherein the TES prevents said interference by the CPP. The fusion protein may also comprise a protein of interest to be delivered to a non-nuclear organelle; a CPP and a TES. The present disclosure also provides methods for treating a non-nuclear organelle associated disorder by administering the fusion protein to a subject in need thereof.

公开(公告)号：US20240254176A1

公开(公告)日：2024-08-01

申请号：US18432505

申请日：2024-02-05

申请人： Larimar Therapeutics, Inc.

发明人： Joan David BETTOUN ,  Rebecca Wissner

IPC分类号： C07K14/47 ,  A61K38/00 ,  A61K47/64 ,  C07K14/005 ,  C12N9/10

CPC分类号： C07K14/47 ,  A61K47/64 ,  C07K14/005 ,  C12N9/104 ,  C12Y203/02 ,  A61K38/00 ,  C07K2319/02 ,  C07K2319/07 ,  C07K2319/50 ,  C12N2740/16322

摘要： The present disclosure provides a fusion protein useful for treating a non-nuclear organelle associated disorder, such as a genetic disorder, e.g., Friedrich's Ataxia. The fusion protein may comprise a protein of interest to be delivered to a non-nuclear organelle; an organelle targeting sequence (OTS); a cell penetrating peptide (CPP); and a target enhancing sequence (TES); wherein the CPP is capable of interference with delivery of the protein of interest to the non-nuclear organelle; and wherein the TES prevents said interference by the CPP. The fusion protein may also comprise a protein of interest to be delivered to a non-nuclear organelle; a CPP and a TES. The present disclosure also provides methods for treating a non-nuclear organelle associated disorder by administering the fusion protein to a subject in need thereof.

公开(公告)号：US20210355177A1

公开(公告)日：2021-11-18

申请号：US17214757

申请日：2021-03-26

申请人： Larimar Therapeutics, Inc.

发明人： Joan David Bettoun ,  Rebecca Wissner

IPC分类号： C07K14/47 ,  C07K14/005 ,  A61K47/64 ,  C12N9/10

摘要： The present disclosure provides a fusion protein useful for treating a non-nuclear organelle associated disorder, such as a genetic disorder, e.g., Friedrich's Ataxia. The fusion protein may comprise a protein of interest to be delivered to a non-nuclear organelle; an organelle targeting sequence (OTS); a cell penetrating peptide (CPP); and a target enhancing sequence (TES); wherein the CPP is capable of interference with delivery of the protein of interest to the non-nuclear organelle; and wherein the TES prevents said interference by the CPP. The fusion protein may also comprise a protein of interest to be delivered to a non-nuclear organelle; a CPP and a TES. The present disclosure also provides methods for treating a non-nuclear organelle associated disorder by administering the fusion protein to a subject in need thereof.

公开(公告)号：US20240228557A1

公开(公告)日：2024-07-11

申请号：US18390884

申请日：2023-12-20

申请人： Larimar Therapeutics Inc

发明人： Joan David BETTOUN ,  Rebecca Wissner

IPC分类号： C07K14/47 ,  A61K47/64 ,  C07K14/005 ,  C12N9/10 ,  A61K38/00

CPC分类号： C07K14/47 ,  A61K47/64 ,  C07K14/005 ,  C12N9/104 ,  C12Y203/02 ,  A61K38/00 ,  C07K2319/02 ,  C07K2319/07 ,  C07K2319/50 ,  C12N2740/16322

摘要： The present disclosure provides a fusion protein useful for treating a non-nuclear organelle associated disorder, such as a genetic disorder, e.g., Friedrich's Ataxia. The fusion protein may comprise a protein of interest to be delivered to a non-nuclear organelle; an organelle targeting sequence (OTS); a cell penetrating peptide (CPP); and a target enhancing sequence (TES); wherein the CPP is capable of interference with delivery of the protein of interest to the non-nuclear organelle; and wherein the TES prevents said interference by the CPP. The fusion protein may also comprise a protein of interest to be delivered to a non-nuclear organelle; a CPP and a TES. The present disclosure also provides methods for treating a non-nuclear organelle associated disorder by administering the fusion protein to a subject in need thereof.

公开(公告)号：US11891420B2

公开(公告)日：2024-02-06

申请号：US17214757

申请日：2021-03-26

申请人： Larimar Therapeutics, Inc.

发明人： Joan David Bettoun ,  Rebecca Wissner

IPC分类号： C07K14/47 ,  A61K47/64 ,  C07K14/005 ,  C12N9/10 ,  A61K38/00

CPC分类号： C07K14/47 ,  A61K47/64 ,  C07K14/005 ,  C12N9/104 ,  C12Y203/02 ,  A61K38/00 ,  C07K2319/02 ,  C07K2319/07 ,  C07K2319/50 ,  C12N2740/16322

摘要： The present disclosure provides a fusion protein useful for treating a non-nuclear organelle associated disorder, such as a genetic disorder, e.g., Friedrich's Ataxia. The fusion protein may comprise a protein of interest to be delivered to a non-nuclear organelle; an organelle targeting sequence (OTS); a cell penetrating peptide (CPP); and a target enhancing sequence (TES); wherein the CPP is capable of interference with delivery of the protein of interest to the non-nuclear organelle; and wherein the TES prevents the interference by the CPP. The fusion protein may also comprise a protein of interest to be delivered to a non-nuclear organelle; a CPP and a TES. The present disclosure also provides methods for treating a non-nuclear organelle associated disorder by administering the fusion protein to a subject in need thereof.